Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

82.22 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 362
Open 82.22
Bid (Size) 80.92 (1)
Ask (Size) 88.50 (2)
Prev. Close 82.22
Today's Range 82.22 - 82.22
52wk Range 73.67 - 99.56
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced.
Investors should take note ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock that remains attractively priced. 
Via Chartmill
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
Via Benzinga

Performance

YTD
-16.14%
-16.14%
1 Month
+7.60%
+7.60%
3 Month
-5.28%
-5.28%
6 Month
-16.14%
-16.14%
1 Year
-4.27%
-4.27%

More News

Read More
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
Via Chartmill
CrowdStrike, KKR, GoDaddy To Join S&P 500 In Quarterly Rebalance; Stocks Jump
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Looking Into Biomarin Pharmaceutical's Recent Short Interest
Via Benzinga
NASDAQ:BMRN is not too expensive for the growth it is showing.
Via Chartmill
Analyst Ratings For Biomarin Pharmaceutical
Via Benzinga
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results
Via Investor's Business Daily
Li Auto Was One Of The Worst-Performing Stocks Last Week: Are These 10 Large-Cap Stocks Losers In Your Portfolio? (May 12-May 18, 2024)
Via Benzinga
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Via Benzinga
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)
Via Benzinga
4 Incomparable Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Via The Motley Fool
Topics Stocks
Exposures US Equities
Walmart To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The 3 Best Biotech Stocks to Buy in May 2024
Via InvestorPlace
Citi Just Cut Its Price Target on These 3 Stocks
Via InvestorPlace
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
Via Chartmill
4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
Via InvestorPlace
BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Don't overlook NASDAQ:BMRN—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.